The Manufacturers Life Insurance Company Sells 91,710 Shares of Icon Plc $ICLR

The Manufacturers Life Insurance Company decreased its position in Icon Plc (NASDAQ:ICLR) by 37.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 150,794 shares of the medical research company’s stock after selling 91,710 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Icon were worth $16,687,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Toth Financial Advisory Corp bought a new stake in Icon in the 4th quarter valued at $27,000. EFG International AG acquired a new position in Icon in the 4th quarter valued at $27,000. Abound Financial LLC bought a new position in Icon during the 4th quarter worth $54,000. Johnson Financial Group Inc. acquired a new stake in shares of Icon during the third quarter worth $71,000. Finally, Blue Trust Inc. boosted its position in shares of Icon by 207.5% in the first quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock valued at $73,000 after acquiring an additional 444 shares during the period. Institutional investors own 95.61% of the company’s stock.

Key Icon News

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Truist reaffirmed its “Buy” rating and raised its price target to $209 from $207, implying substantial upside based on the referenced share price. The target increase signals continued confidence in Icon’s long-term growth prospects. Benzinga analyst rating report
• Positive Sentiment: Icon reported second-quarter revenue of approximately $2.06 billion, above the roughly $2.00 billion consensus estimate, with revenue growing 2.3% from the prior-year period. The earnings call also emphasized a strong surge in bookings, supporting future revenue visibility. Q2 2026 earnings call highlights
• Positive Sentiment: Zacks upgraded ICLR from “Strong Sell” to “Hold,” suggesting its view has improved even though the firm remains cautious. Zacks rating update
• Neutral Sentiment: Quarterly adjusted EPS was $2.56, narrowly above some consensus estimates of $2.55, although another Zacks estimate was $2.57. The mixed comparison makes the earnings beat less decisive for investors. Icon Q2 earnings snapshot
• Negative Sentiment: EPS fell sharply from $3.26 a year earlier, while the earnings call highlighted margin pressures. The weaker profitability, despite higher revenue and bookings, is likely the main factor tempering the bullish analyst commentary. ICON Q2 2026 earnings call transcript

Analysts Set New Price Targets

Several equities analysts recently commented on ICLR shares. Jefferies Financial Group restated a “buy” rating and issued a $165.00 price target on shares of Icon in a research note on Friday, May 29th. DA Davidson set a $164.00 price objective on shares of Icon in a research note on Monday, June 1st. Weiss Ratings downgraded shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, May 29th. BMO Capital Markets increased their target price on shares of Icon from $160.00 to $187.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Finally, UBS Group set a $160.00 target price on shares of Icon in a report on Wednesday, June 24th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $170.40.

Icon Stock Down 1.2%

ICLR stock opened at $163.57 on Friday. Icon Plc has a 52 week low of $66.57 and a 52 week high of $203.91. The business has a 50-day simple moving average of $156.70 and a 200 day simple moving average of $135.62. The company has a quick ratio of 1.14, a current ratio of 0.95 and a debt-to-equity ratio of 0.23. The company has a market cap of $12.52 billion, a PE ratio of 38.40, a price-to-earnings-growth ratio of 8.03 and a beta of 1.22.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, July 29th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.55 by $0.01. Icon had a net margin of 3.99% and a return on equity of 8.02%. The firm had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2 billion. During the same period in the prior year, the company posted $3.26 earnings per share. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. Sell-side analysts anticipate that Icon Plc will post 9.43 EPS for the current fiscal year.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.